VERTEX PHARMACEUTICALS INC / MA Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share
VERTEX PHARMACEUTICALS INC / MA (VRTX) reported Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share of $0.00 per share for the 12-month period ending 2016-12-31, per its 10-K filed 2017-02-23.
Discontinued › Income Statement › Net Income
us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare · last filed 2017-02-23
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2015-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2015-06-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2015-03-31 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for the quarter ending 2014-09-30 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2016 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2015 was $0.00.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- VERTEX PHARMACEUTICALS INC / MA income (loss) from discontinued operations and disposal of discontinued operations, net of tax, per basic share for fiscal 2013 was $0.26.
| Period end | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 3 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 6 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 9 month | Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share 12 month |
|---|---|---|---|---|
| 2016-12-31 | $0.00 10-K · filed 2017-02-23 | |||
| 2015-12-31 | $0.00 10-K · filed 2017-02-23 | |||
| 2015-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | ||
| 2015-06-30 | $0.00 10-Q · filed 2015-08-04 | $0.00 10-Q · filed 2015-08-04 | ||
| 2015-03-31 | $0.00 10-Q · filed 2015-05-04 | |||
| 2014-12-31 | $0.00 10-K · filed 2017-02-23 | |||
| 2014-09-30 | $0.00 10-Q · filed 2015-10-30 | $0.00 10-Q · filed 2015-10-30 | ||
| 2014-06-30 | $0.00 10-Q · filed 2015-08-04 | $0.00 10-Q · filed 2015-08-04 | ||
| 2014-03-31 | $0.00 10-Q · filed 2015-05-04 | |||
| 2013-12-31 | $0.26 10-K · filed 2016-02-16 | |||
| 2013-09-30 | -$0.01 10-Q · filed 2014-11-06 | -$0.03 10-Q · filed 2014-11-06 | ||
| 2012-12-31 | -$0.65 10-K · filed 2015-02-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |